MANE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Veradermics Inc (MANE) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong analyst ratings, large addressable market, and potential first-to-market FDA approval for its product make it a compelling investment opportunity. Despite the lack of recent trading trends or news, the positive sentiment from analysts and the company's innovative product pipeline outweigh the technical and financial weaknesses.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 44.685, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an upward trend in the longer term. The pre-market price is $69.89, below the pivot level of $71.145, with key support at $62.871 and resistance at $79.419.
Strong analyst ratings with multiple Buy and Overweight ratings from reputable firms like Jefferies, Citi, and Leerink.
Large total addressable market ($30B) for the company's product targeting pattern hair loss.
Potential first FDA-approved oral minoxidil for hair loss, addressing a significant unmet need.
Aggressive marketing strategy combining telehealth and direct-to-consumer campaigns.
Financial performance shows no revenue and negative net income (-$28.2M) in Q4
Lack of recent news or significant trading trends from hedge funds, insiders, or Congress.
Technical indicators show bearish momentum (negative MACD) and pre-market price below the pivot level.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $28.2M, though net income improved by 335.63% YoY. EPS increased to -0.8, up 344.44% YoY, indicating some improvement in financial efficiency despite ongoing losses.
Analysts are highly optimistic about Veradermics. Cantor Fitzgerald, Jefferies, Citi, and Leerink initiated coverage with Buy or Overweight ratings, and price targets range from $75 to $85. Analysts highlight the company's innovative product pipeline, large market potential, and high likelihood of success for its Phase 3 study.
